Skip to main content

Table 5 Mean on-treatment changes in A1C (stratified analyses)

From: Real-world utilization patterns and outcomes of colesevelam hcl in the ge electronic medical record

Stratum LOCF within day window Target day Actual day N A1C (%)
Mean Baseline mean Post mean Change mean (95% CI)
Week 16 42 – 140 112      
Monotherapy    96.5 239 7.89 7.51 −0.38 (−0.49, -0.27)
Augment/Switch    96.0 448 8.24 7.80 −0.44 (−0.55, -0.33)
New Combination    96.1 151 8.66 7.63 −1.03 (−1.31, -0.75)
Week 26 42 – 210 182      
Monotherapy    141.5 268 7.90 7.55 −0.35 (−0.46, -0.24)
Augment/Switch    143.7 511 8.28 7.87 −0.40 (−0.51, -0.29)
New Combination    139.3 183 8.69 7.51 −1.18 (−1.46, -0.90)
Week 52 42 – 395 365      
Monotherapy    283.7 188 7.83 7.40 −0.43 (−0.59, -0.27)
Augment/Switch    289.2 439 8.29 7.84 −0.45 (−0.57, -0.33)
New Combination    288.3 222 8.55 7.52 −1.03 (−1.26, -0.80)
  1. P < 0.0001 for all based on t-test of change from baseline to last measure within measurement interval; CI: confidence interval.